UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53

Nature Medicine

Volumn 17, Issue 3, 2011, Pages 347-355

  Wu, Hong ^a   Pomeroy, Scott L ^b   Ferreira, Manuel ^c   Teider, Natalia ^b   Mariani, Juliana ^b   Nakayama, Keiichi I ^d   Hatakeyama, Shigetsugu ^e   Tron, Victor A ^f   Saltibus, Linda F ^a   Spyracopoulos, Leo ^a   Leng, Roger P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KYUSHU UNIVERSITY   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E4; UBIQUITINATION FACTOR E4B; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CARCINOGENESIS; CONTROLLED STUDY; DISEASE MODEL; EMBRYO; EPENDYMOMA; GENE AMPLIFICATION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEDULLOBLASTOMA; MOLECULAR MECHANICS; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; TRANSACTIVATION; UBIQUITINATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; HUMANS; HYDROLYSIS; MICE; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

MUS;

EID: 79952453180     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2283     Document Type: Article

References (42)

1. Farrell, P.J., Allan, G.J., Shanahan, F., Vousden, K.H. & Crook, T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10, 2879-2887 (1991). (Pubitemid 21905305)
2. Crook, T. & Vousden, K.H. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 11, 3935-3940 (1992).
3. Greenblatt, M.S., Bennet, W.P., Hollstein, M. & Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878 (1994). (Pubitemid 24289415)
4. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997). (Pubitemid 27131374)
5. Vogelstein, B., Lane, D. & Levine, A.J. Surfing the p53 network. Nature 408, 307-310 (2000).
6. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
7. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997). (Pubitemid 27220766)
8. Kubbutat, M.H., Jones, S.N. & Vousden, K.H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997). (Pubitemid 27220767)
9. Honda, R., Tanaka, H. & Yasuda, Y. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997). (Pubitemid 28037193)
10. Montes de Oca Luna, R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
11. Jones, S.N., Roe, A.E., Donehower, L.A. & Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208 (1995).
12. Piotrowski, J. et al. Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths. J. Biol. Chem. 272, 23712-23721 (1997). (Pubitemid 27410947)
13. Thrower, J.S., Hoffman, L., Rechsteiner, M. & Pickart, C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102 (2000). (Pubitemid 30009229)
14. Pickart, C.M. Ubiquitin in chains. Trends Biochem. Sci. 25, 544-548 (2000).
15. Rodriguez, M.S., Desterro, J.M., Lain, S., Lane, D.P. & Hay, R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20, 8458-8467 (2000).
16. Lai, Z. et al. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem. 276, 31357-31367 (2001). (Pubitemid 37385007)
17. Grossman, S.R. et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344 (2003). (Pubitemid 36433728)
18. Li, M. et al. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975 (2003). (Pubitemid 37523506)
19. Johnson, E.S., Ma, P.C.M., Ota, I. & Varshavsky, A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270, 17442-17456 (1995).
20. Koegl, M. et al. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96, 635-644 (1999). (Pubitemid 29122806)
21. Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N. & Nakayama, K.I. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 33111-33120 (2001).
22. Tu, D., Li, W., Ye, Y. & Brunger, A.T. Structure and function of the yeast U-box-containing ubiquitin ligase Ufd2p. Proc. Natl. Acad. Sci. USA 104, 15599-15606 (2007). (Pubitemid 350035351)
23. Koepp, D.M., Harper, J.W. & Elledge, S.J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97, 431-434 (1999). (Pubitemid 29231166)
24. Matsumoto, M. et al. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J. 23, 659-669 (2004). (Pubitemid 38282397)
25. Okumura, F., Hatakeyama, S., Matsumoto, M., Kamura, T. & Nakayama, K.I. Functional regulation of FEZ1 by the U-box-type ubiquitin ligase E4B contributes to neuritogenesis. J. Biol. Chem. 279, 53533-53543 (2004). (Pubitemid 40051860)
26. Hosoda, M. et al. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 24, 7156-7169 (2005). (Pubitemid 41679278)
27. Kaneko-Oshikawa, C. et al. Mammalian E4 is required for cardiac development and maintenance of the nervous system. Mol. Cell. Biol. 25, 10953-10964 (2005). (Pubitemid 41747138)
28. Leng, R.P. et al. Pirh2, a p53 induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791 (2003). (Pubitemid 36378882)
29. Sheng, Y. et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat. Struct. Mol. Biol. 15, 1334-1342 (2008).
30. Dornan, D. et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92 (2004). (Pubitemid 38620556)
31. Shi, D. et al. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. USA 106, 16275-16280 (2009).
32. Sui, G. et al. Yin Yang 1 is a negative regulator of p53. Cell 117, 859-872 (2004). (Pubitemid 38798853)
33. Finlay, C.A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13, 301-306 (1993). (Pubitemid 23006907)
34. McCurrach, M.E., Connor, T.M., Knudson, C.M., Korsmeyer, S.J. & Lowe, S.W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 94, 2345-2349 (1997). (Pubitemid 27136877)
35. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D. & Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997). (Pubitemid 27152402)
36. Waldman, T. et al. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 3, 1034-1036 (1997). (Pubitemid 27391962)
37. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998). (Pubitemid 28538613)
38. Saylors, R.L. et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 51, 4721-4723 (1991).
39. Gaspar, N. et al. p53 Pathway dysfunction in primary childhood ependymomas. Pediatr. Blood Cancer 46, 604-613 (2006).
40. Adesina, A.M., Nalbantoglu, J. & Cavenee, W.K. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res. 54, 5649-5651 (1994).
41. Crawford, J.R., MacDonald, T.J. & Packer, R.J. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 6, 1073-1085 (2007). (Pubitemid 350116703)
42. Uziel, T. et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 19, 2656-2667 (2005). (Pubitemid 41627933)